Register entry
HOFFMANN LA ROCHE INC
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 9
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
9| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7504509 | ZELBORAFvemurafenib | substance, product | Oct 2026 |
| 7863288 | ZELBORAFvemurafenib | substance, product | Jun 2029 |
| 9440922 | ALECENSAalectinib hydrochloride | product | Jun 2030 |
| 8741920 | ZELBORAFvemurafenib | substance, product | Jul 2030 |
| 9126931 | ALECENSAalectinib hydrochloride | substance | May 2031 |
| 9365514 | ALECENSAalectinib hydrochloride | product | Mar 2032 |
| 9447089 | ZELBORAFvemurafenib | product | Jun 2032 |
| 10350214 | ALECENSAalectinib hydrochloride | product | Apr 2035 |
| 11433076 | ALECENSAalectinib hydrochloride | product | Apr 2035 |
| Product | Exclusivity | Until |
|---|---|---|
| ALECENSAALECTINIB HYDROCHLORIDE | ODE-477 Orphan drug | Apr 2031 |
Enquiry
Common questions
- Is HOFFMANN LA ROCHE INC FDA approved?
- HOFFMANN LA ROCHE INC holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.